- Home
- SPRO vs COEP Comparison
SPRO vs COEP Comparison
Compare SPRO & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- COEP
- Stock Information
- Founded
- SPRO 2013
- COEP 2017
- Country
- SPRO United States
- COEP United States
- Employees
- SPRO N/A
- COEP N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPRO Health Care
- COEP Health Care
- Exchange
- SPRO Nasdaq
- COEP Nasdaq
- Market Cap
- SPRO 33.0M
- COEP 32.0M
- IPO Year
- SPRO 2017
- COEP N/A
- Fundamental
- Price
- SPRO $2.50
- COEP $9.15
- Analyst Decision
- SPRO Buy
- COEP
- Analyst Count
- SPRO 4
- COEP 0
- Target Price
- SPRO $5.00
- COEP N/A
- AVG Volume (30 Days)
- SPRO 10.8M
- COEP 31.8K
- Earning Date
- SPRO 05-13-2025
- COEP 05-14-2025
- Dividend Yield
- SPRO N/A
- COEP N/A
- EPS Growth
- SPRO N/A
- COEP N/A
- EPS
- SPRO N/A
- COEP N/A
- Revenue
- SPRO $44,584,000.00
- COEP $62,874.00
- Revenue This Year
- SPRO N/A
- COEP N/A
- Revenue Next Year
- SPRO N/A
- COEP N/A
- P/E Ratio
- SPRO N/A
- COEP N/A
- Revenue Growth
- SPRO N/A
- COEP N/A
- 52 Week Low
- SPRO $0.51
- COEP $2.31
- 52 Week High
- SPRO $2.80
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- SPRO 86.18
- COEP 46.80
- Support Level
- SPRO $0.66
- COEP $8.95
- Resistance Level
- SPRO $2.48
- COEP $9.85
- Average True Range (ATR)
- SPRO 0.13
- COEP 0.64
- MACD
- SPRO 0.20
- COEP -0.02
- Stochastic Oscillator
- SPRO 86.36
- COEP 10.47
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.